FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAnixa Biosciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ANIX
Anixa Biosciences, Inc. Stock AnalysisComprehensive stock analysis for Anixa Biosciences, Inc. (ANIX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisANIX
ANIX
Anixa Biosciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ANIX
  1. Home
  2. Stocks
  3. Anixa Biosciences, Inc.

Anixa Biosciences, Inc.

🇺🇸ANIX•NASDAQ

Anixa Biosciences, Inc.

🇺🇸ANIX•NASDAQ
Market cap
$94.21M
Sentiment

Your view on ANIX

Mkt Cap
$94.21M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Anixa Biosciences, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Amit Kumar
Headquarters
3150 Almaden Expressway, San Jose, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Amit Kumar
Headquarters
3150 Almaden Expressway, San Jose, CA, US
Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.

The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19.

The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Anixa Biosciences, Inc. from FRC's valuation model, read against the market price. ANIX last traded at $2.71; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Anixa Biosciences, Inc.. Starting points for Anixa Biosciences, Inc.: EPS -$0.30, beta 0.60 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Anixa Biosciences, Inc.. Anixa Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Anixa Biosciences, Inc.. Trailing twelve-month EPS for Anixa Biosciences, Inc. stands at -$0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 19, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$6.00

average of analysts' targets

 

$6.00

Low $6.00

Median $6.00

High $6.00

 

Analyst Ratings

Buy6 ratings
  • Strong Buy0
  • Buy6
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrJul 2019Next QtrApr 2021Current YearFY Oct 2026Next YearFY Oct 2027
Avg. estimate-$0.11-$0.11-$0.31-$0.32
Low estimate-$0.11-$0.11-$0.31-$0.32
High estimate-$0.11-$0.11-$0.31-$0.32
No. of analysts1111
Year-ago EPS——-$0.34—
Growth——+7.8%—

Revenue Estimate

RevenueCurrent QtrJul 2019Next QtrApr 2021Current YearFY Oct 2026Next YearFY Oct 2027
Avg. estimate$442307.00$605681.00$0.00$34.00M
Low estimate$353845.00$484544.00$0.00$34.00M
High estimate$530768.00$726817.00$0.00$34.00M
No. of analysts141003
Year-ago revenue——$0.00—
Growth————
Recent analyst actions15 rating and price-target changes, latest Sep 22, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 19, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Anixa Biosciences, Inc.. Anixa Biosciences, Inc. has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ANIX20 companies · 7 funds
Compare ANIX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABOSAcumen Pharmaceuticals, Inc.Biotechnology$14M
  • ACTUActuate Therapeutics IncBiotechnology$6M
  • AGENAgenus Inc.Biotechnology$290M
  • ENTXEntera Bio Ltd.Biotechnology$568M
  • HURATuHURA Biosciences, Inc.Biotechnology$87M
  • INOInovio Pharmaceuticals, Inc.Biotechnology$117M
  • IRDOpus Genetics, Inc.Biotechnology$326M
  • SEERSeer, Inc.Biotechnology$80M

More Biotechnology companies

  • ONCYOncolytics Biotech Inc.NASDAQ$44M
  • ONPHOncology Pharma Inc.OTC$109,553
  • ONTTFOxford Nanopore Technologies plcOTC$1.8B
  • OPORFhVIVO plcOTC$59M
  • ORGSOrgenesis Inc.OTC$3M
  • ORICORIC Pharmaceuticals, Inc.NASDAQ$795M
  • ORKAOruka Therapeutics, Inc.NASDAQ$6.5B
  • ORMPOramed Pharmaceuticals Inc.NASDAQ$169M
  • ORPOFOSE Immunotherapeutics S.A.OTC$260M
  • ORYZFOryzon Genomics S.A.OTC$284M
  • OSRHWOSR Holdings, Inc.NASDAQ$8M
  • OSTXOS Therapies IncorporatedAMEX$48M

ETFs holding Anixa Biosciences, Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • IWCiShares Micro-Cap ETF$1.2B in assets0.02%
  • VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
  • VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%
  • VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets0.00%

Largest holders first, then the funds most concentrated in ANIX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Anixa Biosciences, Inc., and how their positions are changing. At a $94.2M market value, institutional positions materially move Anixa Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Anixa Biosciences, Inc. executives and directors. Shares of Anixa Biosciences, Inc. have traded between $2.07 and $4.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Anixa Biosciences, Inc.. Coverage tracks Anixa Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Anixa Biosciences, Inc.

ANIX Analysis
Fair
Past3
Growth2
Health5
Profit1
Value1

News

Latest Market News